Aries Wealth Management boosted its position in Johnson & Johnson (NYSE:JNJ) by 0.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,897 shares of the company’s stock after purchasing an additional 102 shares during the quarter. Johnson & Johnson comprises about 1.9% of Aries Wealth Management’s holdings, making the stock its 13th largest position. Aries Wealth Management’s holdings in Johnson & Johnson were worth $1,793,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in JNJ. Steward Partners Investment Advisory LLC boosted its holdings in shares of Johnson & Johnson by 25.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 166,191 shares of the company’s stock worth $21,447,000 after purchasing an additional 33,496 shares during the last quarter. Narwhal Capital Management increased its stake in Johnson & Johnson by 2.9% in the fourth quarter. Narwhal Capital Management now owns 39,871 shares of the company’s stock valued at $5,145,000 after purchasing an additional 1,135 shares during the last quarter. McCollum Christoferson Group LLC increased its stake in Johnson & Johnson by 0.6% in the fourth quarter. McCollum Christoferson Group LLC now owns 54,449 shares of the company’s stock valued at $7,027,000 after purchasing an additional 340 shares during the last quarter. Stokes Capital Advisors LLC increased its stake in Johnson & Johnson by 7.5% in the fourth quarter. Stokes Capital Advisors LLC now owns 21,083 shares of the company’s stock valued at $2,721,000 after purchasing an additional 1,480 shares during the last quarter. Finally, Iron Financial LLC lifted its position in Johnson & Johnson by 1.8% during the fourth quarter. Iron Financial LLC now owns 4,811 shares of the company’s stock worth $621,000 after buying an additional 87 shares during the period. 67.29% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson stock opened at $136.18 on Friday. The stock has a market capitalization of $363.72 billion, a PE ratio of 16.65, a PEG ratio of 2.08 and a beta of 0.68. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion during the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.74 EPS. On average, equities analysts forecast that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.
Johnson & Johnson announced that its board has initiated a stock repurchase program on Monday, December 17th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to purchase up to 1.5% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
A number of research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “sell” rating in a research note on Tuesday, December 18th. Citigroup increased their price objective on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a report on Monday, February 25th. ValuEngine raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Finally, Barclays reaffirmed an “equal weight” rating and set a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average price target of $143.58.
TRADEMARK VIOLATION NOTICE: This article was reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thestockobserver.com/2019/04/07/aries-wealth-management-buys-102-shares-of-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Trading Strategy
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.